

Trust Headquarters  
 Russell's Hall Hospital  
 Dudley  
 West Midlands  
 DY1 2HQ

**Ref:** FOI-012026-0002203

**Date:** 27<sup>th</sup> February 2026

**Address / Email:**

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000, please see response below.

Can you please help me with the following information.

1. Does your Trust treat patients for the two following conditions?  
 Yes/No

Waldenström macroglobulinaemia (WM) (ICD-10 C88.0) **Yes**  
 Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4) **Yes**

If yes:

1a. How many patients did the Trust treat in calendar year 2025 (January to December) for each of the below conditions?

Waldenström macroglobulinaemia (WM) **14**  
 Marginal zone lymphoma (MZL) **8**

1b. Are there any ongoing clinical trials running at the Trust for each of the below conditions? Please can you advise on any details available on the clinical trials.

Waldenström macroglobulinaemia (WM) **None**  
 Marginal zone lymphoma (MZL) **None**

Please skip 1c to question 2 and 3.

If no:

1c. Which Trust(s) does the Trust refer patients onto for treatment for each of the above conditions?

2. How many patients (and new patients\* if possible) received treatment for Waldenström macroglobulinaemia (WM) in the period 1st July 2025 to 31st December 2025?

Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)		
Regimen	Total Patients	New Patients*
Fludarabine, cyclophosphamide and rituximab (Known as FCR)	<b>0</b>	<b>0</b>

Bendamustine in combination with rituximab (Known as BR)	0	0
Ibrutinib	3	0
Ibrutinib in combination with rituximab	0	0
Zanubrutinib	4	1
Acalabrutinib	0	0
Chemotherapy (Other than the listed regimens)	8	5
Wait and watch - no active treatment and monitoring only	**	**
Any other treatment (Other than the listed regimens)	**	**

\*Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.

**We are unable to answer this as we do not hold the information you have requested in a reportable format.**

3. How many patients (and new patients\* if possible) received treatment for Marginal zone lymphoma (MZL) in the period 1st July 2025 to 31st December 2025?

Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)		
Regimen	Total Patients	New Patients*
Bendamustine in combination with rituximab (Known as BR)	6	6
Chlorambucil in combination with rituximab (Known as CR)	0	0
R CVP (Rituximab + cyclophosphamide + vincristine + prednisolone)	0	0
R CHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)	0	0
Zanubrutinib	1	0
Stem Cell Transplant	0	0
Wait and watch - no active treatment and monitoring only	**	**
Any other treatment (Other than the listed regimens)	1	0

\*Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.

**We are unable to answer this as we do not hold the information you have requested in a reportable format.**

*When information is not in a reportable format*

*The ICO guidance clearly states "FOIA only applies to information that a public authority already holds in recorded form at the time of a request. If you don't hold a particular piece of information that someone has asked for, you don't have to create it".*

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
Trust Headquarters  
Russell's Hall Hospital  
Dudley  
Page 2 of 3

FOI/REF

West Midlands  
DY1 2HQ  
Email: [dgft.dpo@nhs.net](mailto:dgft.dpo@nhs.net)

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
[www.ico.org.uk](http://www.ico.org.uk)

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team**  
**The Dudley Group NHS Foundation Trust**